S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.35 (-2.11%)
BABA   87.22 (-1.22%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.58 (+1.21%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.72 (+0.42%)
DIS   81.01 (-0.30%)
AMC   8.14 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
LON:OXB

Oxford Biomedica (OXB) Share Forecast, Price & News

GBX 290.50
+18.00 (+6.61%)
(As of 04:45 PM ET)
Compare
Today's Range
269
▼
301
50-Day Range
240
▼
451.50
52-Week Range
236.50
▼
575
Volume
367,722 shs
Average Volume
121,922 shs
Market Capitalization
£280.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 752.50
ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines

Oxford Biomedica MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
159.0% Upside
GBX 752.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Oxford Biomedica in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
£12.77 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

See Top Rated MarketRank™ Stocks Here

OXB stock logo

About Oxford Biomedica (LON:OXB) Stock

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

OXB Price History

OXB Stock News Headlines

September 22, 2023 | finance.yahoo.com
Oxford Biomedica First Half 2023 Earnings: Misses Expectations
September 21, 2023 | americanbankingnews.com
Roch Doliveux Acquires 36,130 Shares of Oxford Biomedica plc (LON:OXB) Stock
September 25, 2023 | Chaikin Analytics (Ad)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
September 20, 2023 | finance.yahoo.com
Oxford BioMedica shares soar as vaccine maker raises earnings guidance
July 18, 2023 | finance.yahoo.com
Oxford Biomedica Implements Sapio Sciences' Electronic Laboratory Notebook
May 25, 2023 | msn.com
RBC Capital Markets Reiterates Oxford Biomedica (LSE:OXB) Outperform Recommendation
May 15, 2023 | finance.yahoo.com
Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system
May 5, 2023 | finance.yahoo.com
Why Investors Shouldn't Be Surprised By Oxford Biomedica plc's (LON:OXB) Low P/S
September 25, 2023 | Chaikin Analytics (Ad)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
April 26, 2023 | finance.yahoo.com
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
April 25, 2023 | markets.businessinsider.com
Oxford Biomedica Posts FY Loss
April 21, 2023 | marketwatch.com
2023-2030 "CGT CDMO Market" Share | Global Industry Analysis and Forecast
April 12, 2023 | marketwatch.com
2023-2030 Global CGT CDMO Market is Growing Rapidly with Modern Trend
March 26, 2023 | marketwatch.com
CGT CDMO Market Share and Forecast till 2030
March 15, 2023 | benzinga.com
Oxford BioMedica Stock (OTC:OXBDF), Quotes and News Summary
March 11, 2023 | finance.yahoo.com
As Oxford Biomedica plc's market cap (LON:OXB) drops to UK£484m, insiders might be questioning their decision to buy earlier this year
February 25, 2023 | marketwatch.com
What is a CAGR of CGT CDMO Market? CGT CDMO Market Value in 2028 with Competition Analysis Data of Top Key Players
February 22, 2023 | marketwatch.com
CGT CDMO Market Size Global Research Report, 2023 - 2028
January 30, 2023 | marketwatch.com
CGT CDMO Market Size 2023 Trend and Opportunities, Analysis, CAGR and Value Chain Study, Business Growth to 2028
January 20, 2023 | marketwatch.com
CGT CDMO Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2028
January 12, 2023 | marketwatch.com
CGT CDMO Market Present Development Scenario and Growth Prospects to help you understand the Implications for Your Business | Newest 112 Insights
January 1, 2023 | finance.yahoo.com
A Look At The Intrinsic Value Of Oxford Biomedica plc (LON:OXB)
December 14, 2022 | yahoo.com
Oxford Biomedica Solutions forms new partnerships with three biotechnology companies
December 9, 2022 | marketwatch.com
CGT CDMO Market 2022 : Incredible Possibilities, Growth Analysis and Forecast To 2028
November 22, 2022 | finance.yahoo.com
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
October 25, 2022 | marketwatch.com
CGT CDMO Market Size 2022 Is Changing Consumer Habits, this Industry in the Globe Has Noticed Substantial Growth to 2028 | 112 Pages Report
October 7, 2022 | finance.yahoo.com
Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree
See More Headlines
Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:OXB
CUSIP
N/A
CIK
N/A
Web
www.oxfordbiomedica.co.uk
Phone
+44-1865-783000
Fax
N/A
Employees
894
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 752.50
High Stock Price Forecast
GBX 1,010
Low Stock Price Forecast
GBX 495
Forecasted Upside/Downside
+157.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-61,630,000.00
Net Margins
-51.78%
Pretax Margin
N/A
Return on Equity
-30.64%
Return on Assets
-12.05%

Debt

Debt-to-Equity Ratio
57.10
Current Ratio
3.32
Quick Ratio
1.67

Sales & Book Value

Annual Sales
£119.02 million
Price / Sales
2.37
Cash Flow
GBX 97.17 per share
Price / Cash Flow
3.01
Book Value
GBX 178 per share
Price / Book
1.64

Miscellaneous

Outstanding Shares
96,600,000
Free Float
N/A
Market Cap
£282.21 million
Optionable
Not Optionable
Beta
1.03
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Stuart Paynter (Age 49)
    CFO, Company Sec. & Director
    Comp: $832k
  • Dr. Frank Mathias (Age 61)
    CEO & Director
  • Mr. Nick Page
    Chief Operations Officer
  • Dr. James Miskin Ph.D.
    Chief Technical Officer
  • Dr. Kyriacos Mitrophanous Ph.D.
    Chief Scientific Officer
  • Mr. Matthew Treagus
    Chief Information Officer & Chief of Staff
  • Sophia Bolhassan
    Head of Investor Relations
  • Ms. Natalie Louise Walter
    Gen. Counsel
  • Ms. Lisa James
    Chief People Officer
  • Ms. Sarah Macleod
    Head of Communications

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













OXB Stock - Frequently Asked Questions

Should I buy or sell Oxford Biomedica stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OXB shares.
View OXB analyst ratings or view top-rated stocks.

What is Oxford Biomedica's stock price forecast for 2023?

2 brokers have issued twelve-month target prices for Oxford Biomedica's shares. Their OXB share price forecasts range from GBX 495 to GBX 1,010. On average, they predict the company's share price to reach GBX 752.50 in the next year. This suggests a possible upside of 157.6% from the stock's current price.
View analysts price targets for OXB or view top-rated stocks among Wall Street analysts.

How have OXB shares performed in 2023?

Oxford Biomedica's stock was trading at GBX 442.50 at the beginning of 2023. Since then, OXB shares have decreased by 34.0% and is now trading at GBX 292.15.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL).

What is Oxford Biomedica's stock symbol?

Oxford Biomedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB."

How do I buy shares of Oxford Biomedica?

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Oxford Biomedica's stock price today?

One share of OXB stock can currently be purchased for approximately GBX 292.15.

How much money does Oxford Biomedica make?

Oxford Biomedica (LON:OXB) has a market capitalization of £282.21 million and generates £119.02 million in revenue each year. The biopharmaceutical company earns £-61,630,000.00 in net income (profit) each year or GBX (0.46) on an earnings per share basis.

How many employees does Oxford Biomedica have?

The company employs 894 workers across the globe.

How can I contact Oxford Biomedica?

Oxford Biomedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The official website for the company is www.oxfordbiomedica.co.uk. The biopharmaceutical company can be reached via phone at +44-1865-783000.

This page (LON:OXB) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -